Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study

MLA

Maja Rajevic, et al. “Cardiovascular Safety of Tiotropium Respimat vs HandiHaler in the Routine Clinical Practice: A Population-Based Cohort Study.” PLoS ONE, vol. 12, no. 4, Jan. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....489117fd219fd02dd55a61bc8827880b&authtype=sso&custid=ns315887.

APA

Maja Rajevic, Roberto Da Cas, Giuseppe Traversa, Mauro Venegoni, Stefania Spila-Alegiani, Valentino Conti, Mariangela Rossi, & Francesco Trotta. (2017). Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study. PLoS ONE, 12(4).

Chicago

Maja Rajevic, Roberto Da Cas, Giuseppe Traversa, Mauro Venegoni, Stefania Spila-Alegiani, Valentino Conti, Mariangela Rossi, and Francesco Trotta. 2017. “Cardiovascular Safety of Tiotropium Respimat vs HandiHaler in the Routine Clinical Practice: A Population-Based Cohort Study.” PLoS ONE 12 (4). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....489117fd219fd02dd55a61bc8827880b&authtype=sso&custid=ns315887.